Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Major study tracks Real-World MG care in china

NCT ID NCT06700616

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

This study follows about 1,200 people with myasthenia gravis (MG) across China to understand how the disease is treated in real-world clinics. Researchers will track symptoms, daily living abilities, quality of life, and healthcare use every 6 months until 2027. The goal is to learn more about current treatments and patient outcomes, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,199 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will recruit patients diagnosed with MG by a physician. The diagnosis of MG patients newly diagnosed prior to enrollment should be based on the clinical characteristics of MG and at least one of the following criteria: (a) Positive serology tests for acetylcholine receptor antibody (AChR Ab), muscle-specific kinase antibody (MuSK Ab), or lipoprotein-related protein 4 (LRP4 Ab); (b) Results of electrophysiological studies (repetitive stimulation, single-fiber electromyography, or both) related to synaptic transmission disorder at the neuromuscular junction; (c) Positive pharmacological test results (such as neostigmine methylsulfate test). Previously diagnosed patients must have a documented MG diagnosis accepted by clinical physician.

Ages

0 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: This study will enroll patients of all ages who are diagnosed with MG of all MGFA classifications by physicians. 1. Patients must have the following data to be enrolled in this study: * MGFA classification * MG-ADL score 2. MG patients or their legal guardians/representatives are able to sign the Informed Consent Form (ICF). Exclusion Criteria: 1. Patients aged ≥18 years with ocular myasthenia gravis (MGFA class I) lasting for more than 2 years; 2. Patients who are currently participating in an interventional clinical trial cannot be enrolled in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myasthenia gravis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myasthenia gravis

Contacts and locations

Locations

  • Research Site

    Beijing, China

  • Research Site

    Chengdu, China

  • Research Site

    Fuzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guiyang, China

  • Research Site

    Harbin, China

  • Research Site

    Hebei, China

  • Research Site

    Henan, China

  • Research Site

    Inner Mongolia, China

  • Research Site

    Jiangsu, China

  • Research Site

    Lanzhou, China

  • Research Site

    Nanning, China

  • Research Site

    Qingdao, China

  • Research Site

    Taiyuan, China

  • Research Site

    Tianjin, China

  • Research Site

    Ürümqi, China

  • Research Site

    Wenzhou, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

  • Research Site

    Yinchuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.